Effects of intrastriatal injections of glutamate receptor antagonists on the severity of paroxysmal dystonia in the dtsz mutant

European Journal of Pharmacology

Volumn 563, Issue 1-3, 2007, Pages 102-108

  Sander, Svenja Esther ^a   Richter, Angelika ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Basal ganglia; Dyskinesia; Glutamate; Movement disorder; Striatum

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; 3 AMINO 1 HYDROXY 2 PYRROLIDINONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; DIZOCILPINE; GLUTAMATE RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DYSTONIA; MICROINJECTION; MONOTHERAPY; MUTANT; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BASAL GANGLIA; CAUDATE NUCLEUS; CRICETINAE; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSTONIA; EXCITATORY AMINO ACID ANTAGONISTS; MICROINJECTIONS; MOVEMENT; MUSCLE CONTRACTION; MUTATION; POSTURE; PUTAMEN; PYRROLIDINONES; QUINOXALINES; REACTION TIME; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; SEVERITY OF ILLNESS INDEX; VALINE;

EID: 34247142452     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.01.067     Document Type: Article

References (34)

1. Bernard V., and Bolam J.P. Subcellular and subsynaptic distribution of the NR1 subunit of the NMDA receptor in the neostriatum and globus pallidus of the rat: co-localization at synapses with the GluR2/3 subunit of the AMPA receptor. Eur. J. Neurosci. 10 (1998) 3721-3736
2. Calabresi P., Pisani A., Mercuri N.B., and Bernardi G. The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. Trends Neurosci. 19 (1996) 19-24
3. Chan W.S., Yeung C.W., Chung E.K., Lau W.K., Chan Y.S., and Yung K.K. Differential expression of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate glutamate receptors in the rat striatum during postnatal development. NeuroSignals 12 (2003) 302-309
4. Crossman A.R. Functional anatomy of movement disorders. J. Anat. 196 (2000) 519-525
5. Fahn S., Bressman S.B., and Marsden C.D. Classification of dystonia. Adv. Neurol. 78 (1998) 1-10
6. Gernert M., Hamann M., Bennay M., Loscher W., and Richter A. Deficit of striatal parvalbumin-reactive GABAergic interneurons and decreased basal ganglia output in a genetic rodent model of idiopathic paroxysmal dystonia. J. Neurosci. 20 (2000) 7052-7058
7. Hamann M., and Richter A. Effects of striatal injections of GABA(A) receptor agonists and antagonists in a genetic animal model of paroxysmal dystonia. Eur. J. Pharmacol. 443 (2002) 59-70
8. Hamann M., and Richter A. Striatal increase of extracellular dopamine levels during dystonic episodes in a genetic model of paroxysmal dyskinesia. Neurobiol. Dis. 16 (2004) 78-84
9. Hamann M., Sander S.E., and Richter A. Age-dependent alterations of striatal calretinin interneuron density in a genetic animal model of primary paroxysmal dystonia. J. Neuropathol. Exp. Neurol. 64 (2005) 776-781
10. Herrling P.L. Pharmacology of the corticocaudate excitatory postsynaptic potential in the cat: evidence for its mediation by quisqualate- or kainate-receptors. Neuroscience 14 (1985) 417-426
11. Kaur S., Ozer H., and Starr M. MK 801 reverses haloperidol-induced catalepsy from both striatal and extrastriatal sites in the rat brain. Eur. J. Pharmacol. 332 (1997) 153-160
12. Kawaguchi Y. Neostriatal cell subtypes and their functional roles. Neurosci. Res. 27 (1997) 1-8
13. Köhling R., Koch U.R., Hamann M., and Richter A. Increased excitability in cortico-striatal synaptic pathway in a model of paroxysmal dystonia. Neurobiol. Dis. 16 (2004) 236-245
14. Kulkarni S.K., and Naidu P.S. Tardive dyskinesia: an update. Drugs Today (Barc) vol. 37 (2001) 97-119
15. Li L., Murphy T.H., Hayden M.R., and Raymond L.A. Enhanced striatal NR2B-containing N-methyl-d-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. J. Neurophysiol. 92 (2004) 2738-2746
16. Löscher W., and Richter A. The glycine/NMDA receptor ligand (+)-HA-966 but not d-cycloserine has potent antidystonic efficacy in a genetic animal model of dystonia. Eur. J. Pharmacol. 239 (1993) 245-247
17. Löscher W., Fisher Jr. J.E., Schmidt D., Fredow G., Honack D., and Iturrian W.B. The sz mutant hamster: a genetic model of epilepsy or of paroxysmal dystonia?. Mov. Disord. 4 (1989) 219-232
18. Maldonado-Irizarry C.S., and Kelley A.E. Differential behavioral effects following microinjection of an NMDA antagonist into nucleus accumbens subregions. Psychopharmacology (Berl) 116 (1994) 65-72
19. Mink J.W. The basal ganglia and involuntary movements. Arch. Neurol. 60 (2003) 1365-1368
20. Mintz E.M., Marvel C.L., Gillespie C.F., Price K.M., and Albers H.E. Activation of NMDA receptors in the suprachiasmatic nucleus produces light-like phase shifts of the circadian clock in vivo. J. Neurosci. 19 (1999) 5124-5130
21. Morin L.P., and Wood R.I. A Stereotaxic Atlas of the Golden Hamster Brain (2001), Academic Press, San Diego
22. Morrow B.A., Elsworth J.D., Zito C., and Roth R.H. Biochemical and behavioral anxiolytic-like effects of R(+)HA-966 at the level of the ventral tegmental area in rats. Psychopharmacology (Berl) 143 (1999) 227-234
23. Nardocci N., Fernandez-Alvarez E., Wood N.W., Spacy S.D., and Richter A. The paroxysmal dyskinesias. In: Guerrini R., Aicardi J., Andermann F., and Hallett M. (Eds). Epilepsy and Movement Disorders (2002), Cambridge Univ. Press, Cambridge 125-139
24. Nobrega J.N., Richter A., Jiwa D., Raymond R., and Löscher W. Alterations in N-methyl-d-aspartate receptor binding in dystonic hamster brains. Brain Res. 744 (1997) 161-165
25. Nobrega J.N., Raymond R., Barlow K., Hamann M., and Richter A. Changes in AMPA receptor binding in an animal model of inborn paroxysmal dystonia. Exp. Neurol. 176 (2002) 371-376
26. Parsons C.G., Danysz W., and Quack G. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect. 11 (1998) 523-569
27. Rehders J.H., Löscher W., and Richter A. Evidence for striatal dopaminergic overactivity in paroxysmal dystonia indicated by microinjections in a genetic rodent model. Neuroscience 97 (2000) 267-277
28. Richter A., and Löscher W. Behavioural response to pharmacologic manipulation of serotonin receptors in the genetically dystonic hamster. Pharmacol. Biochem. Behav. 52 (1995) 655-665
29. Richter A., and Löscher W. Pathology of idiopathic dystonia: findings from genetic animal models. Prog. Neurobiol. 54 (1998) 633-677
30. Richter A., Fredow G., and Löscher W. Antidystonic effects of the NMDA receptor antagonists memantine, MK-801 and CGP 37849 in a mutant hamster model of paroxysmal dystonia. Neurosci. Lett. 133 (1991) 57-60
31. Richter A., Löscher W., and Löschmann P.A. The AMPA receptor antagonist NBQX exerts antidystonic effects in an animal model of idiopathic dystonia. Eur. J. Pharmacol. 231 (1993) 287-291
32. Sander S.E., Hamann M., and Richter A. Age-related changes in striatal NOS-immunoreactive interneurons in the dystonic dt(sz) mutant hamster. Neuropathol. Appl. Neurobiol. 32 (2006) 74-82
33. Vilagi I., Kocsis P., Tarnawa I., and Banczerowski-Pelyhe I. Effect of glutamate receptor antagonists on excitatory postsynaptic potentials in striatum. Brain Res. Bull. 46 (1998) 483-486
34. Vitek J.L. Pathophysiology of dystonia: a neuronal model. Mov. Disord. 17 Suppl 3 (2002) S49-S62